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Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network 
Methicillin-Resistant Staphylococcus aureus, 2009 
 
ABCs Areas 
California (3 county San Francisco Bay area); Colorado (5 Denver area county); Connecticut; Georgia (8 county Atlanta area); Maryland (Baltimore 
City and County); Minnesota (2 metro Twin City counties); New York (1 Rochester county); Oregon (3 county Portland area); Tennessee (1 Nashville 
county).  Note, the population under surveillance changed from 2008 (Bold).   
 
ABCs Population 
The surveillance areas represent 19,311,576 persons 
Source: National Center for Health Statistics bridged-race vintage 2009 postcensal file.   
 
ABCs Case Definition 
Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease:  isolation of MRSA from a normally sterile site in a resident of the surveillance 
area in 2009.  Cases of disease are classified into one of three epidemiologic classifications.  A case is classified as hospital-onset (HO) if the MRSA 
culture was obtained on or after the fourth calendar day of hospitalization, where admission is hospital day 1;  as healthcare-associated 
community-onset (HACO) if the culture was obtained in an outpatient setting  or before the fourth calendar day of hospitalization and had one of 
more of the following: 1) a history of hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the 
presence of a central vascular catheter within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously mentioned 
criteria are met. 
 
ABCs Methodology 
ABCs personnel routinely contacted all microbiology laboratories serving acute care hospitals in their area to identify cases. Standardized case 
report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified 
case.  Convenience samples of isolates were collected and sent to CDC for routine testing, including: antimicrobial susceptibility testing, toxin 
testing and SCCmec typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; an inferred PFGE algorithm was 
developed based on microbiologic and molecular characteristics of isolates.  The algorithm has been validated for use with isolates collected 
though this surveillance only (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html).  Regular laboratory audits were performed to 
ensure completeness of case detection. 
Rates of invasive MRSA disease among all patients were calculated using population estimates for 2009.  Cases with unknown race were assigned 
race based on distribution of known race and gender by EIP site.  Confidence intervals for nationally estimated incidence rates of disease and 
mortality were calculated based on the gamma distribution (Stat Med, 1997 16:791-801).  Rates of invasive MRSA disease among patients who are 
undergoing chronic dialysis treatment were calculated using the December 31, 2008 point prevalent counts of patients on dialysis from the United 
States Renal Data System (USRDS) (http://www.usrds.org/adr.htm).    
 
ABCs Results 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distribution of cases, deaths and PFGE  type by Epidemiological Classification 
MRSA 
Class 
No. (Rate)  
Cases b 
No. (Rate)  
Death c 
Inferred PFGE Type (n,%)d 
Tot N USA100 USA300 
USA500/ 
Iberian 
CA 982 (5.1) 102 (0.5) 300 63 (21.0) 213 (71.0) 9 (3.0) 
HCA a 4,508 (23.3)  720 (3.7) 1,037 560 (54.0) 353 (34.0) 82 (8.9) 
HO 1,198 (6.2) 281 (1.5) 264 150 (56.8) 80 (30.3) 28 (10.6) 
HACO 3,310 (17.1) 439 (2.3) 773 410 (53.0) 273 (35.3) 64 (8.3) 
a
 HCA: Healthcare-associated invasive MRSA infections; sum of patients that are 
classified as  either HO or HACO 
b 
n= 115 epidemiologic category unknown 
c
 n=10;  epidemiologic category unknown 
d
 isolates were eligible for testing at CDC 
Reported Racial/Ethnic ABCs Profiles 
Race                               No.    (Rate) a          
White  3,301 (23.7) 
Black  2,067 (57.6) 
Other  237 (13.3) 
 
Unknown race (n=642) distributed amongst known 
a 
Cases per 100,000 population for ABCs areas (crude rates) 
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Age Group 
Incidence of Invasive MRSA, by 
 Epidemiological Class and Age Group 
2009 
CA HACO HO
Reported Cases on Chronic Dialysis (n=1003) 
Dialysis and Access Type No.   (%) 
Type of dialysis   
      Peritoneal  28 (2.8) 
      Hemodialysis  973  (97.0) 
AV Fistula/Graft 339 (34.8) 
CVC 550 (56.5) 
Unknown 84  (8.6) 
      Unknown  0 (0) 
Reported Clinical Syndrome by Epidemiological Class 
Syndrome a 
CA 
(n=982) 
HACO 
(n=3310) 
HO 
(n=1198) 
Bloodstream infection   
with other syndrome 551 1813 468 
with no other syndrome 205 1063 461 
Pneumonia 175 461 243 
Lower Respiratory Infection b 61 123 93 
Osteomyelitis 125 374 114 
Endocarditis 79 178 44 
Cellulitis 175 260 70 
Wounds     
Surgical c 15 194 59 
Decubitus/Pressure Ulcers 32 150 35 
Other wounds/skin abscesses d 16 39 9 
Traumatic 18 13 12 
a 
Some case patients had more than one syndrome. 
b 
Lower Respiratory Infection is defined as:  a patient with pneumonia 
documented in their discharge summary, who has a positive MRSA non-
sterile respiratory specimen with accompanying chest radiology results 
documenting any of the following: bronchopneumonia/pneumonia, air 
space density/opacity, new or changed infiltrates. 
c
 Combines deep tissue/organ infection and infection of a surgical 
wound, post operatively. 
d 
Category includes skin abscess, necrotizing fasciitis, gangrene, non-
traumatic wounds. 
National Estimates and Adjusted Incidence Rates for Mortality among Cases 
Epidemiologic Class Estimated No. Mortality Rate 
(Confidence Interval) a 
CA 1,675 0.55 (0.44-0.67) 
HCA 12,262 4.00 (3.71-4.32) 
HO 4,786 1.56 (1.38-1.77) 
HACO 7,476 2.44 (2.21-2.69) 
Overall b 14,100 4.59 (4.28-4.93) 
a 
National Estimates and Mortality Rate (no. per 100,000 population per year) are 
adjusted for age, race, gender and receipt of chronic dialysis using 2009 US Census Data 
b 
10 cases could not be classified into an epidemiological category or category is 
unknown, and therefore are counted in the overall estimate only. 
National Estimates and Adjusted Incidence Rates of Invasive MRSA Infections 
Epidemiologic 
Category 
Estimated Cases of Infection 
Non-Dialysis Patients Dialysis Patients Total 
 Estimated 
No. 
Incidence Rate  
(Confidence Interval)a  
Estimated 
No. 
Incidence Rate 
(Confidence Interval)b  
Estimated 
No. 
Incidence Rate 
(Confidence Interval) 
CA 15,211 4.96 (4.65-5.29) NA NA 15,211 4.96 (4.65-5.29) 
HCA 56,785 18.53 (17.91-19.17) 16,094 4190.52 (3926.26-4474.32) 72,879 23.75 (23.04-24.47) 
      HO 17,294 5.64 (5.30-6.00) 1,941 505.94 (414.97-618.29) 19,235 6.27 (5.91-6.65) 
      HACO 39,491 12.88 (12.36-13.42) 14,153 3688.96 (3441.69-3955.81) 53,644 17.47 (16.87-18.10) 
Overall c 73,810  24.07 (23.37-24.79) 16,056 4184.99 (3921.04-4468.50) 89,867 29.27 (28.49-30.08) 
a
 National Estimates and Incidence (no. per 100,000 population per year) are adjusted for age, race, gender and receipt of chronic dialysis using 2009 US 
Census Data.  
b National Estimates and Incidence (no. per 100,000 dialysis patients per year) for dialysis patients are adjusted for age, race and gender using 2008 USRDS 
point prevalence data.   
c 
115 cases could not be classified into an epidemiological category or category is unknown, and therefore are counted in the overall estimate only.   
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National Metric for Healthy People 2020 and the Department of Health and Human Services Action Plan to Prevent Healthcare-Associated 
Infections 
 
 
 
 
 
 
ABCs Discussion 
Surveillance data from 2009 represent the fifth full year of performing population-based surveillance for invasive MRSA infections through the 
Emerging Infections Program/Active Bacterial Core Surveillance Activity. Several changes in operations include addition of new variables to capture 
details on dialysis and access type and presentation of target measures to evaluate the reduction of healthcare-associated invasive MRSA 
infections.  
 
Tables/figures have been added to (1) summarize details regarding type of dialysis and the type of access used for hemodialysis, indicating the 
majority of cases on chronic dialysis treatment were using  central venous catheter for hemodialysis at the time of invasive MRSA culture; and (2)  
report metrics to measure progress in prevention of healthcare-associated invasive MRSA infections in the United States as part of Healthy People 
2020 and the Department of Health and Human Services Action Plan to Prevent Healthcare-Associated Infections 
(http://www.hhs.gov/ash/initiatives/hai/actionplan/). Overall, compared to the baseline incidence (2007-2008 calendar years) identified in the HHS 
Action Plan, there was a decrease of 12.3%: a decrease on course to reach the target of a 50% reduction in 2013. 
 
Because incidence of invasive MRSA infection is higher among dialysis patients compared to the general population,2 and  increasing awareness 
and importance is being placed on preventing bloodstream infections among this population in the United States, we are displaying national 
estimates overall, and separately for dialysis and non-dialysis patients.  Also, adjustment for dialysis was refined to account for receipt of chronic 
dialysis only whereas previous reports adjusted for receipt of chronic and acute dialysis in the past year.  Receipt of acute dialysis accounts for ~7% 
of all cases with a history of dialysis in the prior year.     
 
Citation 
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For more information, visit our web sites:  http://www.cdc.gov/abcs, http://www.cdc.gov/mrsa 
 
 Disease Rate  Estimate of Cases in United States. a 
Baseline (07-08) 2009 % Change Baseline (07-08) 2009 Difference 
HCA  27.08 23.75 -12.3 82,000 72,900 -9,100 
a
  Disease Rate (no. per 100,000 population per year) and National Estimates are adjusted for age, race, 
gender and receipt of chronic dialysis using 2009 US Census Data
 
